Baloxavir Marboxil

English Name: Baloxavir Marboxil

CAS No.: 1985606-14-1

Molecular formula: C27H23F2N3O7S

Molecular weight: 571.55

Overview: in February 2018, baloxavirmarboxil (trade name: xofluza), a new anti influenza drug developed by Shionogi of Japan and jointly studied with Roche of Switzerland, was accelerated in Japan and approved for listing. Baloxavir axetil is an innovative cap dependent endonuclease inhibitor. It is also one of the few new drugs in the world that can inhibit the proliferation of influenza virus. In June 2018, the US Food and Drug Administration (FDA) accepted the new drug marketing application of baloxavir axetil and granted it priority review qualification.

Properties

Baloxavir axetil is an innovative cap dependent endonuclease inhibitor. It is also one of the few new drugs in the world that can inhibit the proliferation of influenza virus.

CAS No.

1985606-14-1

Formula

C27H23F2N3O7S

Molecular Mass

571.54900

Exact Mass

571.12200

PSA

124.84000

Logp

3.39410

IUPAC

[(3R)-2-[(11S)-7,8-difluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-9,12-dioxo-5-oxa-1,2,8-triazatricyclo[8.4.0.03,8]tetradeca-10,13-dien-11-yl]oxymethyl methyl carbonate

Matter Classification

organic

Category

Density

1.57±0.1 g/cm3(Predicted)

Boiling Point

712.8±70.0 °C(Predicted)

Appearance

White powder

HS Code

29420000

Send your message to this supplier